Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presented By Alan Venook at 2016 ASCO Annual Meeting

Published byDamon Lawrence Conley Modified over 8 years ago

Similar presentations

Presentation on theme: "Presented By Alan Venook at 2016 ASCO Annual Meeting"— Presentation transcript:

1 Presented By Alan Venook at 2016 ASCO Annual Meeting
Impact of primary tumor location on<br /> Overall Survival and Progression Free Survival <br />in patients with metastatic colorectal cancer: <br /> Analysis of CALGB/SWOG (Alliance) Presented By Alan Venook at 2016 ASCO Annual Meeting

2 Presented By Alan Venook at 2016 ASCO Annual Meeting
CALGB/SWOG 80405 Presented By Alan Venook at 2016 ASCO Annual Meeting

3 Presented By Alan Venook at 2016 ASCO Annual Meeting
CALGB/SWOG 80405 Presented By Alan Venook at 2016 ASCO Annual Meeting

4 Presented By Alan Venook at 2016 ASCO Annual Meeting
Slide 4 Presented By Alan Venook at 2016 ASCO Annual Meeting

5 Embryology: The origin of the colon
Presented By Alan Venook at 2016 ASCO Annual Meeting

6 Presented By Alan Venook at 2016 ASCO Annual Meeting
Slide 6 Presented By Alan Venook at 2016 ASCO Annual Meeting

7 CALGB 80405: Side of primary tumor<br /> Methods
Presented By Alan Venook at 2016 ASCO Annual Meeting

8 Presented By Alan Venook at 2016 ASCO Annual Meeting
Slide 8 Presented By Alan Venook at 2016 ASCO Annual Meeting

9 Patient Characteristics by Tumor Side, 80405 (KRAS wt)
Presented By Alan Venook at 2016 ASCO Annual Meeting

10 80405: Overall Survival by Sidedness
Presented By Alan Venook at 2016 ASCO Annual Meeting

11 80405: OS by Sidedness (Bevacizumab)<br />
Presented By Alan Venook at 2016 ASCO Annual Meeting

12 80405: OS by Sidedness (Cetuximab)<br />
Presented By Alan Venook at 2016 ASCO Annual Meeting

13 Presented By Alan Venook at 2016 ASCO Annual Meeting
80405: Sidedness is Prognostic<br />Progression Free Survival (PFS) Presented By Alan Venook at 2016 ASCO Annual Meeting

14 80405: Sidedness is Prognostic<br /> Overall Survival (OS)
Presented By Alan Venook at 2016 ASCO Annual Meeting

15 Presented By Alan Venook at 2016 ASCO Annual Meeting
Slide 15 Presented By Alan Venook at 2016 ASCO Annual Meeting

16 Median OS by Sidedness:<br />80405 and FIRE-3*
Presented By Alan Venook at 2016 ASCO Annual Meeting

17 Presented By Alan Venook at 2016 ASCO Annual Meeting
80405: Sidedness Predictive for Biologics <br /> Biologic by 1° Side Interaction Presented By Alan Venook at 2016 ASCO Annual Meeting

18 Overall Survival by Sidedness and Biologic
Presented By Alan Venook at 2016 ASCO Annual Meeting

19 OS by Biologic<br /> Right-sided primary
Presented By Alan Venook at 2016 ASCO Annual Meeting

20 OS by Biologic<br />Left-sided primary
Presented By Alan Venook at 2016 ASCO Annual Meeting

21 CALGB/SWOG 80405: <br /> Sidedness in KRAS wt mCRC
Presented By Alan Venook at 2016 ASCO Annual Meeting

22 <br /> Sidedness in mCRC: Biological surrogate
Presented By Alan Venook at 2016 ASCO Annual Meeting

23 Presented By Alan Venook at 2016 ASCO Annual Meeting
<br /> Correlative Studies<br /> Tumor / Plasma / Serum > samples<br /> Presented By Alan Venook at 2016 ASCO Annual Meeting

24 CALGB/SWOG 80405: Limitations
Presented By Alan Venook at 2016 ASCO Annual Meeting

25 Presented By Alan Venook at 2016 ASCO Annual Meeting
80405: Sidedness Prognostic in KRAS mut patients<br /> (KRAS mutant pts, pre-amendment cohort) Presented By Alan Venook at 2016 ASCO Annual Meeting

26 80405: Exploratory Analysis (wt v mut )<br />
Presented By Alan Venook at 2016 ASCO Annual Meeting

27 Sidedness in mCRC: Take Home Messages
Presented By Alan Venook at 2016 ASCO Annual Meeting

28 Stay Tuned: <br /> Next three presentations
Presented By Alan Venook at 2016 ASCO Annual Meeting

29 Presented By Alan Venook at 2016 ASCO Annual Meeting
Sidedness in mCRC Presented By Alan Venook at 2016 ASCO Annual Meeting

30 Presented By Alan Venook at 2016 ASCO Annual Meeting
ACKNOWLEDGEMENTS Presented By Alan Venook at 2016 ASCO Annual Meeting

31 Presented By Alan Venook at 2016 ASCO Annual Meeting
THANK YOU Presented By Alan Venook at 2016 ASCO Annual Meeting

32 Rachel Pearline, MD, MPH<br /> in memorium: 1977 - 2015
Presented By Alan Venook at 2016 ASCO Annual Meeting

33 Presented By Alan Venook at 2016 ASCO Annual Meeting
Slide 33 Presented By Alan Venook at 2016 ASCO Annual Meeting

Download ppt "Presented By Alan Venook at 2016 ASCO Annual Meeting"

Similar presentations

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.
Cáncer de Colon: Resultados de los estudios CRYSTAL, FIRE3 y CALGB-80405 Andrés Cervantes.

Cáncer de Colon: Resultados de los estudios CRYSTAL, FIRE3 y CALGB Andrés Cervantes.
Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal.

Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal.
Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.

Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.
Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.

Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.
*University Hospital Gasthuisberg, Leuven, Belgium

*University Hospital Gasthuisberg, Leuven, Belgium
Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB 80203.

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
Colorectal Cancer Abstracts Oral Session: 6/6/10 Alan P. Venook, M.D. University of California, San Francisco.

Colorectal Cancer Abstracts Oral Session: 6/6/10 Alan P. Venook, M.D. University of California, San Francisco.
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.
Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts 4032-4035 Jeffrey Meyerhardt,

Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts Jeffrey Meyerhardt,
Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,
Www.OncologyEducation.ca Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by CapeOX plus BEV or single agent (s/a) BEV.

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by CapeOX plus BEV or single agent (s/a) BEV.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.
Presented By Michael Overman at 2016 ASCO Annual Meeting

Presented By Michael Overman at 2016 ASCO Annual Meeting
Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Similar presentations

Ads by Google